Business Description
Circio Holding ASA is a Norwegian biotechnology company, founded in 2010 and headquartered in Oslo, that focuses on developing cancer treatments based on circular RNA technology and immunotherapy. Its lead program, TG01, is a cancer vaccine designed to target specific cancer-driving mutations and is currently being tested in clinical trials for multiple myeloma, pancreatic cancer, and lung cancer. The company's circVec platform is used to engineer functional circular RNA molecules inside human cells, with ongoing partnerships supporting both its formulation and the development of a macrophage-based cell therapy approach to fighting cancer.
